Skip to main content
PRME
NASDAQ Life Sciences

Prime Medicine Extends Cash Runway into 2027, Advances Key Gene Editing Programs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.38
Mkt Cap
$615.683M
52W Low
$1.11
52W High
$6.94
52W Position info
205% above low
Off High info
51% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

PRME has more than doubled off its 52-week low of $1.11.

Summary

Prime Medicine reported Q1 2026 financial results, extending its cash runway into 2027 and confirming on-track progress for key gene editing programs, including two IND/CTA filings and continued BLA dialogue.


Key Events · Earnings and Guidance · PRME

  • Cash Runway Extended

    Reported cash, cash equivalents, investments, and restricted cash of $149.2 million as of March 31, 2026, providing a cash runway into 2027. This is a significant positive development following previous 'going concern' warnings.

  • Pipeline Progress Confirmed

    On track to file IND and/or CTA for PM577 (Wilson Disease) in H1 2026 and for PM647 (AATD) mid-2026, with initial clinical data from both expected in 2027. Regulatory dialogue continues with the FDA toward a potential BLA filing for PM359 (CGD).

  • Leadership Strengthened

    Svetlana Makhni was appointed Chief Financial Officer in April 2026, bringing over 20 years of experience in biotechnology and healthcare finance.

  • Financial Results

    Q1 2026 R&D expenses decreased to $34.1 million (from $40.6 million in Q1 2025) due to strategic focus and workforce reduction. G&A expenses increased to $17.4 million (from $13.3 million in Q1 2025) primarily due to arbitration-related legal expenses. Net loss slightly improved to $49.1 million (from $51.9 million in Q1 2025).


Analysis · PRME · Life Sciences

This 8-K provides crucial updates for Prime Medicine, particularly in light of its previous 'going concern' warning. The reported cash position of $149.2 million and projected runway into 2027 significantly de-risks the company's near-term financial stability. Furthermore, the on-track progress for two IND/CTA filings and continued regulatory dialogue for a potential BLA filing demonstrate strong operational execution in advancing its pipeline. The appointment of a new CFO also strengthens the leadership team, providing a more positive outlook despite ongoing arbitration costs.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRME was trading at $3.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $615.7M. The 52-week trading range was $1.11 to $6.94. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRME - Latest Insights

PRME
Nov 10, 2026, 9:41 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $3.76
Real-time Price: $3.90 info
Change: +$0.1405 (+4%) info
Market Cap: $707.37M info
PRME
Nov 10, 2026, 4:43 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $3.90 info
Change: +$0.110 (+3%) info
Market Cap: $707.37M info
PRME
Nov 10, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $3.90 info
Change: +$0.100 (+3%) info
Market Cap: $707.37M info
PRME
Nov 10, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.81
Real-time Price: $3.90 info
Change: +$0.0899 (+2%) info
Market Cap: $707.37M info
PRME
Oct 28, 2026, 1:53 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.16
Real-time Price: $3.90 info
Change: -$1.26 (-24%) info
Market Cap: $707.37M info